JP2002519305A - 骨吸収阻害用の組成物および方法 - Google Patents

骨吸収阻害用の組成物および方法

Info

Publication number
JP2002519305A
JP2002519305A JP2000556389A JP2000556389A JP2002519305A JP 2002519305 A JP2002519305 A JP 2002519305A JP 2000556389 A JP2000556389 A JP 2000556389A JP 2000556389 A JP2000556389 A JP 2000556389A JP 2002519305 A JP2002519305 A JP 2002519305A
Authority
JP
Japan
Prior art keywords
group
geranyl
geranylgeranyl
nitrogen
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000556389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002519305A5 (enExample
Inventor
レスカ，アルフレツド・エイ
スコルニツク，エドワード・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817172.1A external-priority patent/GB9817172D0/en
Priority claimed from GBGB9822330.8A external-priority patent/GB9822330D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2002519305A publication Critical patent/JP2002519305A/ja
Publication of JP2002519305A5 publication Critical patent/JP2002519305A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000556389A 1998-06-24 1999-06-21 骨吸収阻害用の組成物および方法 Withdrawn JP2002519305A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US9040198P 1998-06-24 1998-06-24
US9291998P 1998-07-15 1998-07-15
GBGB9817172.1A GB9817172D0 (en) 1998-08-06 1998-08-06 Compositions and methods for inhibiting bone resorption
GB60/090,401 1998-10-13
GBGB9822330.8A GB9822330D0 (en) 1998-10-13 1998-10-13 Compositions and methods for inhibiting bone resorption
GB9822330.8 1998-10-13
GB60/092,919 1998-10-13
GB9817172.1 1998-10-13
PCT/US1999/013967 WO1999067809A1 (en) 1998-06-24 1999-06-21 Compositions and methods for inhibiting bone resorption

Publications (2)

Publication Number Publication Date
JP2002519305A true JP2002519305A (ja) 2002-07-02
JP2002519305A5 JP2002519305A5 (enExample) 2006-08-10

Family

ID=27451815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000556389A Withdrawn JP2002519305A (ja) 1998-06-24 1999-06-21 骨吸収阻害用の組成物および方法

Country Status (6)

Country Link
US (2) US6432931B1 (enExample)
EP (1) EP1088333A4 (enExample)
JP (1) JP2002519305A (enExample)
AU (1) AU757104B2 (enExample)
CA (1) CA2336201A1 (enExample)
WO (1) WO1999067809A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213658A (ja) * 2005-02-04 2006-08-17 Hisamitsu Pharmaceut Co Inc 骨粗鬆症治療用外用剤
JP2014530810A (ja) * 2011-10-04 2014-11-20 コヨーテ ファーマシューティカルズ インコーポレイテッド ゲラニルゲラニルアセトン誘導体

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022963A1 (en) * 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
KR20030048129A (ko) * 2000-11-08 2003-06-18 산텐 세이야꾸 가부시키가이샤 파르네실초산을 유효 성분으로 하는 각결막 질환 치료제
JP4205432B2 (ja) * 2001-03-30 2009-01-07 日清オイリオグループ株式会社 骨代謝改善剤
AU2002366444A1 (en) * 2001-11-08 2003-09-09 Merck & Co., Inc. Compounds useful in the treatment of anthrax
MXPA04006027A (es) * 2001-12-21 2004-09-27 Procter & Gamble Metodo para el tratamiento de trastornos de los huesos.
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
WO2003057136A2 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
DE60317061T2 (de) * 2002-05-10 2008-07-24 F. Hoffmann-La Roche Ag Ibandronsäure zur behandlung und vorbeugung von osteoporose
EP1596870B2 (en) * 2002-12-20 2011-04-06 F. Hoffmann-La Roche AG High dose ibandronate formulation
JP4463274B2 (ja) * 2003-06-27 2010-05-19 明 小谷 ビスホスホネート錯体
PL1855674T3 (pl) 2005-03-02 2015-01-30 Merck Sharp & Dohme Kompozycja do hamowania katepsyny K
US7704656B2 (en) * 2005-03-23 2010-04-27 Xerox Corporation Photoconductive imaging member
DE602006005597D1 (de) * 2005-12-27 2009-04-23 Ipca Lab Ltd Verbesserter Herstellungsprozess von 4-Amino-Hydroxybutyliden-1,1-bisphosphonischer Säure und ihrer Salze
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
US20080164004A1 (en) * 2007-01-08 2008-07-10 Anastasia Kolesnichenko Method and system of electromagnetic stirring for continuous casting of medium and high carbon steels
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
US20130085283A1 (en) * 2011-10-04 2013-04-04 Coyote Pharmaceuticals, Inc. Geranylgeranylacetone derivatives
US9045403B2 (en) 2012-02-29 2015-06-02 Coyote Pharmaceuticals, Inc. Geranyl geranyl acetone (GGA) derivatives and compositions thereof
WO2014055440A1 (en) * 2012-10-01 2014-04-10 Coyote Pharmaceuticals, Inc. Preparation of gga and derivatives thereof and their co-crystallization with urea or thiourea
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof
WO2014101049A1 (en) 2012-12-27 2014-07-03 Kimberly-Clark Worldwide, Inc. Water soluble essential oils and their use
US10532124B2 (en) 2012-12-27 2020-01-14 Kimberly-Clark Worldwide, Inc. Water soluble farnesol analogs and their use
WO2014151697A1 (en) * 2013-03-15 2014-09-25 Coyote Pharmaceuticals, Inc. Therapeutic uses for geranylgeranyl acetone and derivatives thereof
WO2014151719A1 (en) * 2013-03-15 2014-09-25 Coyote Pharmaceuticals, Inc. Sublingual formulations including geranylgeranylacetone and geranylgeranylacetone derivatives
KR102363895B1 (ko) * 2020-03-02 2022-02-17 영남대학교 산학협력단 염증 질환 또는 면역 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB938712A (en) * 1961-05-24 1963-10-02 Angeli Inst Spa Farnesyl acetic esters
JPS5612114B2 (enExample) 1974-06-07 1981-03-18
JPS5573642A (en) * 1978-11-28 1980-06-03 Kuraray Co Ltd Farnesyl-acetic ester derivative
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS57106644A (en) * 1980-12-20 1982-07-02 Kotobuki Seiyaku Kk Farnesence derivative, mucosa stabilizer comprising it as active ingredient, and its preparation
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4518528A (en) 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US4933165A (en) 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5316765A (en) 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
EP0448697B1 (fr) 1989-10-13 1996-04-10 Neurofit Analogues de la vitamine a, leurs applications, notamment en tant que molecules cytotrophiques et cytoprotectrices, et compositions pharmaceutiques les contenant
US5210272A (en) 1990-02-16 1993-05-11 Prototek, Inc. Process for forming a fluoromethyl ketone
US5101068A (en) 1990-02-16 1992-03-31 Prototek Inc. Magnesium fluoromalonates
CA2036962C (en) 1990-02-26 1998-09-15 Ann E. Decamp Process for the desilylation of a 4-silyloxy-tetrahydro-pyran-2-one
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5157025A (en) 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
DE69226820T2 (de) 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
EP0522576A3 (en) 1991-07-12 1993-07-14 Hoechst Aktiengesellschaft Aminoethane-1,1-bisphosphonic acids and aminoethane-1,1-alkylphospinic/phosphonic acids, process of their preparation and their use
US5128328A (en) 1991-10-25 1992-07-07 American Home Products Corporation Heterocyclic bisphosphonic acid derivatives
DE69320176T2 (de) 1992-02-21 1999-04-08 Merck & Co., Inc., Rahway, N.J. Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5985838A (en) 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
TW257765B (enExample) 1993-08-25 1995-09-21 Merck & Co Inc
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5712261A (en) * 1993-10-04 1998-01-27 Magnin; David R. Method for preventing or treating hypertriglyceridemia
JP3674956B2 (ja) * 1994-01-28 2005-07-27 エーザイ株式会社 抗骨粗鬆症剤
US5447922A (en) 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5574025A (en) 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
IL113246A (en) 1995-04-04 2004-08-31 Yissum Res Dev Co Bisphosphonates and pharmaceutical compositions containing them
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5618964A (en) 1995-06-07 1997-04-08 Bristol-Myers Squibb Company Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method
JPH0930977A (ja) * 1995-07-20 1997-02-04 Tsuneo Nanba 升麻抽出物を含有する骨疾患治療剤
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US5817816A (en) * 1996-06-20 1998-10-06 Meiji Seika Kaisha, Ltd. Sesquiterpene derivatives having progesterone receptor binding inhibitory activity
US6083979A (en) 1996-10-09 2000-07-04 University Of Pittsburgh Geranylgeraniol/lovastatin: a novel approach to blocking cancer transformation without cytotoxicity
US5777326A (en) * 1996-11-15 1998-07-07 Sensor Corporation Multi-anode time to digital converter
US5763646A (en) 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Process for manufacturing simvastatin from lovastatin or mevinolinic acid
JPH11130670A (ja) 1997-10-27 1999-05-18 Oyo Seikagaku Kenkyusho 骨粗鬆症治療剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213658A (ja) * 2005-02-04 2006-08-17 Hisamitsu Pharmaceut Co Inc 骨粗鬆症治療用外用剤
JP2014530810A (ja) * 2011-10-04 2014-11-20 コヨーテ ファーマシューティカルズ インコーポレイテッド ゲラニルゲラニルアセトン誘導体

Also Published As

Publication number Publication date
AU4702599A (en) 2000-01-10
CA2336201A1 (en) 1999-12-29
WO1999067809A1 (en) 1999-12-29
WO1999067809A9 (en) 2001-03-22
EP1088333A1 (en) 2001-04-04
US20020082244A1 (en) 2002-06-27
US6699850B2 (en) 2004-03-02
EP1088333A4 (en) 2005-08-10
US6432931B1 (en) 2002-08-13
AU757104B2 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
JP2002519305A (ja) 骨吸収阻害用の組成物および方法
JP2002506030A (ja) 骨再吸収の阻害方法
US20040097468A1 (en) Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
JP2001253827A (ja) 骨粗鬆症を治療するための組成物および方法
JP3479780B2 (ja) 骨吸収を抑制する方法
JP2002501757A (ja) ストレス応答性キナーゼのモジュレーターの特定方法
JP2002518457A (ja) 骨吸収阻害用の組成物および方法
JP2003529365A (ja) ゲラニルゲラニルジホスフェートシンターゼを阻害するために有用な化合物の同定方法
KR20030027007A (ko) 엔도텔린 길항제를 사용하여 암 및 이와 관련된 통증을치료하는 방법
US20020151459A1 (en) Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase
JP2002527386A (ja) 骨形成調節方法
AU775239B2 (en) Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase
US20040180862A1 (en) Compositions and methods for inhibiting bone resorption
KR20060004924A (ko) ＮＦ-κＢ 활성화 특이적 억제제 및 심혈관 질환의 염증과정 치료 방법
US20030078211A1 (en) Compositions and methods for inhibiting bone resorption
AU2001252997A1 (en) Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
AU2002303925A1 (en) Compositions and methods for inhibiting bone resorption

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060612

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080826